Market Overview

Motus GI Appoints Jeff Hutchison as VP of U.S. Sales and Commercial Operations

Share:

– Hutchison brings extensive background in innovative GI product
sales and will lead development of commercial organization in
preparation for 2019 launch –

Motus
GI Holdings, Inc.
, (NASDAQ:MOTS) ("Motus GI" or the "Company"), a
medical technology company dedicated to improving clinical outcomes and
enhancing the cost-efficiency of colonoscopy, announced today the
appointment of Jeff Hutchison as Vice President of U.S. Sales and
Commercial Operations. Mr. Hutchison will be responsible for building
Motus GI's U.S. sales organization and driving the Company's pre-launch
commercial activities ahead of the planned launch of the Pure-Vu®
System
into the inpatient market in 2019. The Pure-Vu® System, the
Company's flagship, FDA-cleared medical device system, enables
physicians to rapidly cleanse the colon during the colonoscopy procedure
to facilitate improved visualization and enable a quality exam.
Challenges with bowel preparation for inpatient colonoscopy represent a
significant area of unmet need that directly affects clinical outcomes
and increases the cost of care in a market segment that comprises
approximately 1.5 million annual procedures in the U.S. and
approximately 4 million annual procedures worldwide.

"The appointment of Jeff Hutchison as our VP of U.S. Sales and
Commercial Operations is a critical step in our strategic roadmap to the
commercial launch of the Pure-Vu® System in the inpatient colonoscopy
market," commented Mark
Pomeranz, CEO of Motus GI
. "Jeff is an experienced and senior sales
leader in the GI space who was a key player in the launch and commercial
build out of BÂRRX prior to its acquisition by Covidien as well as its
continued growth under Covidien and then Medtronic. He knows how to
build and lead a sales organization to drive new market opportunities in
the GI space and that is exactly why he is joining Motus GI now."

Mr. Hutchison joins Motus GI following over 25 years of executive sales
leadership and new market development experience in the medical device
industry. He most recently served as Vice President of U.S. Sales for
Bio2 Medical. Prior to that, he served as Area Vice President of Sales
for Medtronic GI Solutions (NYSE:MDT) where he led the Western Division
of Medtronic's GI business, managed the integration of two major
acquisitions and led the growth of the organization from 33 territories
and 4 regions to 135 territories and 18 regions. Previously, he served
as Director of U.S. Sales for BÂRRX Medical, where he led the U.S. sales
organization and drove commercialization of BÂRRX's endoscopic treatment
devices for Barrett's Esophagus. Mr. Hutchison was an integral part of
the BÂRRX's acquisition team when it was purchased by Covidien in 2011
(Covidien was later acquired by Medtronic). During that time, he oversaw
the hiring of 50 professionals. Prior to BÂRRX, Mr. Hutchison spent 17
years at Boston Scientific (NYSE:BSX) in a variety of sales, sales
management and market development roles in the endoscopy and cardiology
divisions.

"The Pure-Vu® System presents an opportunity to deliver significant
clinical and economic benefits not only for patients but for all
stakeholders involved in colonoscopy for hospitalized patients including
physicians, nursing staff and hospital administrators," said Hutchison.
"I am thrilled to be joining Motus GI at this time when I can play a
pivotal role in building our commercial organization and driving our
commercialization plan focused on the inpatient hospital market. I am
really looking forward to bringing this product to market and seeing us
realize its potential."

About Motus GI and the Pure-Vu® System

Motus GI Holdings, Inc. is a medical technology company, with
subsidiaries in the U.S. and Israel, dedicated to improving clinical
outcomes and enhancing the cost-efficiency of colonoscopy. The Company's
flagship product is the Pure-Vu® System, a 510(k) U.S. Food and Drug
Administration cleared medical device indicated to help facilitate the
cleaning of a poorly prepared colon during the colonoscopy procedure.
The device integrates with standard colonoscopes to enable cleaning
during the procedure while preserving standard procedural workflow and
techniques. The Pure-Vu® System has received CE mark approval in Europe.
The Pure-Vu® System is currently being introduced on a pilot basis in
the U.S. market, and the Company is planning to initiate a full
commercial launch focused on the inpatient colonoscopy market in the
U.S. and select international markets in 2019. Challenges with bowel
preparation for inpatient colonoscopy represent a significant area of
unmet need that directly affects clinical outcomes and increases the
cost of care in a market segment that comprises approximately 1.5
million annual procedures in the U.S. and approximately 4 million annual
procedures worldwide. Motus GI believes the Pure-Vu® System may improve
outcomes and lower costs for hospitals by reducing the time to
successful colonoscopy, minimizing delayed and aborted procedures, and
improving the quality of an exam. In clinical studies to date, the
Pure-Vu® System significantly increased the number of patients with an
adequate cleansing level, according to the Boston Bowel Preparation
Scale Score, a validated assessment instrument.

For more information, visit www.motusgi.com
and connect with the Company on Twitter,
LinkedIn,
Facebook
and Google+.

Forward-Looking Statements

This press release contains certain forward-looking statements.
Forward-looking statements are based on the Company's current
expectations and assumptions. The Private Securities Litigation Reform
Act of 1995 provides a safe-harbor for forward-looking statements. These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, "expect," "anticipate," "intend," "plan,"
"believe," "estimate," "potential," "predict," "project," "should,"
"would" and similar expressions and the negatives of those terms,
including without limitation, risks inherent in the development and
commercialization of potential products, uncertainty in the timing and
results of clinical trials or regulatory approvals, maintenance of
intellectual property rights or other risks discussed in the Company's
Form 10-K filed on March 28, 2018, and its other filings with the
Securities and Exchange Commission. Prospective investors are cautioned
not to place undue reliance on such forward-looking statements, which
speak only as of the date hereof. The Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of
new information, future events or otherwise.

View Comments and Join the Discussion!